Sionna Therapeutics at The Citizens Life Sciences Conference
Sionna Therapeutics, Inc. (NASDAQ: SION), a clinical-stage biopharmaceutical company, is at the forefront of transforming cystic fibrosis (CF) treatment. The company is dedicated to launching innovative medicines aimed at improving the functionality of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. They are excited to announce their participation in The Citizens Life Sciences Conference, happening soon.
Presentation Details
On May 7, 2025, at 12:30 p.m. ET, Sionna's management will share insights at this prestigious event. Attendees can expect a live stream of the presentation available on Sionna's Investors section of their website, along with a replay for those who cannot attend live.
Mission to Change Lives
At the core of Sionna’s mission is the commitment to alter the existing treatment paradigm for CF. The company aims to create novel therapies that can fundamentally restore CFTR's function. Sionna's innovative approach involves directly stabilizing the nucleotide-binding domain 1 (NBD1) of CFTR, which is essential for improving health outcomes for individuals suffering from CF.
Understanding Cystic Fibrosis
Cystic fibrosis is a genetic disorder that severely impacts the lungs and digestive system. It primarily affects the movement of salt and water in and out of cells, leading to thick, sticky mucus buildup. For many years, treatment options have been limited, making breakthroughs in pharmaceutical development vital for patients and their families.
Sionna’s Innovative Drug Development
With over ten years of extensive research backing their efforts, Sionna is pioneering a pipeline of small molecules designed to rectify the faults caused by the F508del mutation, a common genetic issue in CF patients. This genetic mutation affects the CFTR protein's ability to function properly, and Sionna's goal is to re-establish this functionality as closely to normal as possible.
Additional Therapies
In addition to their primary NBD1 stabilizers, Sionna is also developing an array of complementary CFTR modulators. These modulators aim to enhance the overall function of CFTR, leading to better clinical responses and improved quality of life for patients living with CF.
Investor Relations Approach
Sionna is committed to transparency and open communication with their investors. They utilize their Investor Relations website as a crucial tool for sharing nonpublic information and maintaining compliance with regulatory obligations. It’s essential for investors to stay updated through the company's website as well as its press releases and public communications.
Contact Information
For media inquiries, Adam Daley from CG Life can be contacted at 212.253.8881 or via email. Investors seeking information on Sionna's advancements can reach out to Juliet Labadorf at ir@sionnatx.com.
Frequently Asked Questions
What is Sionna Therapeutics focused on?
Sionna Therapeutics is dedicated to developing innovative medicines aimed at normalizing the function of the CFTR protein in cystic fibrosis patients.
When will Sionna present at the Citizens Life Sciences Conference?
Sionna will present on May 7, 2025, at 12:30 p.m. ET during The Citizens Life Sciences Conference.
How can I view Sionna’s presentation?
The presentation will be available via a live webcast on Sionna’s Investor Relations webpage, with a replay accessible afterward.
What role does NBD1 play in cystic fibrosis treatment?
NBD1 is critical for CFTR protein function, and stabilizing this domain is central to Sionna's approach to improving therapy outcomes for cystic fibrosis.
Who can I contact for more information?
For media inquiries, contact Adam Daley at CG Life. Investors can reach out directly to Juliet Labadorf via the provided email.
